Interventional Strategies in Glioblastoma Tumor Models

Glioblastoma remains the most aggressive form of primary brain tumour, characterised by extensive intratumoural heterogeneity, diffuse infiltration and a highly immunosuppressive microenvironment. Preclinical efforts have therefore focused on refining animal and cellular models to test interventions that target tumour-intrinsic drivers, modulate the immune milieu and overcome the blood–tumour barrier. Genetic strategies include exploitation of synthetic lethal interactions in tumours with defined mutations and chromatin-remodelling defects, while pharmacological approaches range from blood–brain barrier-penetrant small molecules to inhibitors of tumour-associated kinases. Emerging models employ orthotopic patient-derived xenografts and genetically engineered hosts, including zebrafish and rodent systems, to permit real-time imaging, high-throughput screening and mechanistic dissection of tumour–stroma cross-talk. Together, these platforms are accelerating the translation of novel therapeutic concepts, from immune-modulating agents to barrier-disrupting adjuvants, with a view to improving outcomes in this devastating disease.

Research from Nature Portfolio

Investigations into chromatin-associated complexes have revealed that loss of the tumour suppressor PTEN sensitises glioblastoma cells to inhibition of the histone chaperone DAXX. Disruption of DAXX–H3.3 interactions reprogrammes oncogene and tumour suppressor expression, selectively impairing growth of PTEN-deficient models and prolonging survival in orthotopic rodent implants. This work highlights a synthetic-lethal framework for targeting epigenetic vulnerabilities in genetically stratified tumours. In parallel, a zebrafish orthotopic glioblastoma xenograft system has been deployed as an in vivo visual readout to identify small molecules capable of traversing an intact brain barrier. Using human glioblastoma cell implants in transparent embryos, researchers discovered a novel compound that efficiently crosses endothelial barriers, inhibits tumour progression and validates the model as a platform for rapid anti-GBM drug screening.

Interventional Strategies in Glioblastoma Tumor Models publication trend

The graph below shows the total number of articles in interventional strategies in glioblastoma tumor models across all publications each year (not limited to Nature Index journals).

Technical terms

Glioblastoma: A highly malignant primary brain tumour characterised by rapid growth and diffuse infiltration.

Blood–tumour barrier (BTB): A specialised endothelial interface that restricts chemotherapeutic entry into brain tumours.

Orthotopic xenograft: Transplantation of human tumour cells into the anatomically corresponding site of an animal host.

Syngeneic model: A tumour model in which cancer cells and host share an identical genetic background, preserving immune competence.

Tumour microenvironment (TME): The complex network of non-malignant cells, extracellular matrix and signalling factors surrounding a tumour.

References

1. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications (2017).
2. Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model. Scientific Reports (2017).
3. Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma. EMBO Molecular Medicine (2023).
4. A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo. eLife (2024).
5. Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model. Acta Neuropathologica Communications (2024).